Development of an amoebic gill disease vaccine to protect Atlantic salmon

开发阿米巴鳃病疫苗以保护大西洋鲑鱼

• 批准号: LP160101762
• 负责人: Dr Andrew Bridle
• 金额: $ 21.17万
• 依托单位: University of Tasmania
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-12-22 至 2023-12-22
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP160101762
• 关键词: Development; amoebic; gill; disease; vaccine

This project aims to identify candidate vaccine antigens and produce an experimental vaccine against amoebic gill disease (AGD) that will benefit the Tasmanian and international Atlantic salmon aquaculture industries. AGD is the most significant health problem affecting Atlantic salmon aquaculture in Tasmania. In the last decade, AGD has become a legitimate health threat to the multibillion dollar global Atlantic salmon industry. A solution is needed before AGD fully establishes itself in the largest Atlantic salmon producing nations. The expected outcome of this project is the development of a commercial vaccine that should significantly benefit the Australian and international aquaculture industries.

该项目旨在确定候选疫苗抗原并生产针对阿米巴鳃病（AGD）的实验性疫苗，这将有利于塔斯马尼亚和国际大西洋鲑鱼水产养殖业。 AGD 是影响塔斯马尼亚大西洋鲑鱼养殖的最重要的健康问题。在过去的十年中，AGD 已成为对价值数十亿美元的全球大西洋鲑鱼产业的合法健康威胁。在 AGD 在最大的大西洋鲑鱼生产国中完全站稳脚跟之前，需要找到一个解决方案。该项目的预期成果是开发出一种商业疫苗，该疫苗将大大有利于澳大利亚和国际水产养殖业。